Skip to main content
Emily Chew, MD, Ophthalmology, Bethesda, MD, NIH Clinical Center

EmilyYing H NChewMD

Ophthalmology • Bethesda, MD

Retinal Disease

Physician

Join to view full profile

Dr. Chew is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Chew's full profile

Already have an account?

Summary

  • I am a board certified ophthalmologist specialized in medical retina. I am currently the the Director of the Division of Epidemiology and Clinical Applications (DECA), at the National Eye Institute, the National Institutes of Health in Bethesda, Maryland. I am also the Chief of the Clinical Trials . I obtained my medical degree and residency training in ophthalmology at the University of Toronto, School of Medicine, in Toronto, Canada. I completed my fellowship in Medical Retina at the Wilmer Eye Institute, the Johns Hopkins Medical Institutes and the U. of Nijmegen, the Netherlands.

    My research interest includes designing and conducting phase I/II clinical trials and epidemiologic studies in chronic retinovascular diseases such as age-related macular degeneration, diabetic retinopathy, the leading causes of blindness in the US. I am actively involved with leadership roles in the conduct of clinical trials such as Age-Related Eye Disease Study, the Age-Related Eye Disease Study 2, the Actions to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study, the Macular Telangiectasia Project (Mac Tel Project) with phase 1 to 3 clinical trial using ciliary neurotrophic factor (CNTF). I chair the current international study, known as the AMD Ryan Initiative Study (ARIS), which evaluates the natural course of early AMD. Finally, I collaborate with colleagues at the National Library of Medicine (NLM/NIH) utilizing of artificial intelligence/deep learning on the detection and progression of age-related macular degeneration.

Education & Training

  • University of Toronto Faculty of Medicine
    University of Toronto Faculty of MedicineClass of 1977

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 1987 - 2024
  • American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

  • Fellow (FAAO) American Academy of Ophthalmology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration  
    Srinivas R Sadda, Brandon Busbee, Emily Y Chew, Neil M Bressler, JAMA
  • Optical Coherence Tomography Minimum Intensity as an Objective Measure for the Detection of Hydroxychloroquine Toxicity  
    Emily Y Chew, Catherine Cukras, Paul A Sieving, Investigative Ophthalmology and Visual Science

Press Mentions

  • AI-Based Systems Can Help Identify Rapidly Advancing Age-Related Macular Degeneration
    AI-Based Systems Can Help Identify Rapidly Advancing Age-Related Macular DegenerationMarch 14th, 2023
  • Cohort Finds Lutein and Zeaxanthin Reduce Effects of AMD
    Cohort Finds Lutein and Zeaxanthin Reduce Effects of AMDJune 13th, 2022
  • Week in Review: Inhaled Steroids Raise IOP, Antioxidants Appear Safe in AMD Patients, Brolucizumab Approved for DME
    Week in Review: Inhaled Steroids Raise IOP, Antioxidants Appear Safe in AMD Patients, Brolucizumab Approved for DMEJune 4th, 2022
  • Join now to see all

Grant Support

  • Mactel2National Eye Institute2010–2011
  • Mactel1National Eye Institute2010–2011
  • Medical Retina FellowshipNational Eye Institute2009–2011
  • FIND (Familial Investigation Of Nephropathy In Diabetes)National Eye Institute2009–2011
  • Age-Related Eye Disease Follow-Up Study (AREDS) Follow-Up StudyNational Eye Institute2009–2011
  • Accord (Action To Control Cardiovascular Risk In Diabetes)National Eye Institute2009–2011
  • Serum Factors In Diabetic EyesNational Eye Institute2009–2010
  • Ranibizumab (Rhufab V2) For Advanced Ocular Disease Of VNational Eye Institute2005
  • Evaluation/Diagnosis- Potential Subject-RetinovascularNational Eye Institute2005
  • Evaluation-Treatment Protocol-Patients- Retinal DiseaseNational Eye Institute2005
  • Accord(Action-Control Cardiovascular Risk In Diabetes)National Eye Institute2005
  • The Raman StudyNational Eye Institute2003–2005
  • Serum Factors In Diabetic EyesNational Eye Institute2003–2005
  • FIND (Familial Investigation Of Nephropathy In Diabetes)National Eye Institute2003–2005
  • DPP (Diabetes Prevention Program)National Eye Institute2003–2005
  • Diabetic Macular Edema StudyNational Eye Institute2002–2005
  • Age-Related Eye Disease Study (AREDS)National Eye Institute2002–2005
  • Screening For Evaluation/Diagnosis Of Potential SubjectsNational Eye Institute2004
  • Ranibizumab For Advanced Ocular Disease Of VHL DiseaseNational Eye Institute2004
  • Evaluation &Treatment Protocol For PatientsNational Eye Institute2004
  • Accord Action To Control Cardiovascular Risk In DiabetesNational Eye Institute2004
  • Screening For The Evaluation/Diagnosis Of Potential SubjNational Eye Institute2003
  • Range Study Of Lutein Supplementation In Persons Over AGNational Eye Institute2003
  • Evaluation And Treatment Protocol For Patients With RetiNational Eye Institute2003
  • Antioxidant For DmeNational Eye Institute2003
  • Accord (Action To Control Cardiovascular Risk In DiabeteNational Eye Institute2003
  • Screening For Retinovascular DiseasesNational Eye Institute2002
  • Range Study Of Lutein Supplementation Over Age 60National Eye Institute2002
  • Evaluation And Treatment Protocol Of Retinal DiseaseNational Eye Institute2002

Professional Memberships

Other Languages

  • Chinese (Cantonese)

Hospital Affiliations

Dr. Emily Chew, Dr. Emily Chew, MD, Dr. E Chew, Dr. Emily Ying H N Chew